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Nasal high-flow therapy for newborn infants in special care nurseries
Abstract

Background: Nasal high-flow therapy is an alternative to nasal continuous positive airway pressure (CPAP)
as a means of respiratory support for newborn infants. The efficacy of high-flow therapy in nontertiary special
care nurseries is unknown.
Methods: We performed a multicenter, randomized, noninferiority trial involving newborn infants (age;
gestational age, ≥31 weeks) in special care nurseries in Australia. Newborn infants with respiratory distress
and a birth weight of at least 1200 g were assigned to treatment with either high-flow therapy or CPAP. The
primary outcome was treatment failure within 72 hours after randomization. Infants in whom high-flow
therapy failed could receive CPAP. Noninferiority was determined by calculating the absolute difference in the
risk of the primary outcome, with a noninferiority margin of 10 percentage points.
Results: A total of 754 infants (mean gestational age, 36.9 weeks, and mean birth weight, 2909 g) were
included in the primary intention-to-treat analysis. Treatment failure occurred in 78 of 381 infants (20.5%) in
the high-flow group and in 38 of 373 infants (10.2%) in the CPAP group (risk difference, 10.3 percentage
points; 95% confidence interval [CI], 5.2 to 15.4). In a secondary per-protocol analysis, treatment failure
occurred in 49 of 339 infants (14.5%) in the high-flow group and in 27 of 338 infants (8.0%) in the CPAP
group (risk difference, 6.5 percentage points; 95% CI, 1.7 to 11.2). The incidences of mechanical ventilation,
transfer to a tertiary neonatal intensive care unit, and adverse events did not differ significantly between the
groups.
Conclusions: Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in a
significantly higher incidence of treatment failure than CPAP when used in nontertiary special care nurseries
as early respiratory support for newborn infants with respiratory distress. (Funded by the Australian National
Health and Medical Research Council and Monash University; HUNTER Australian
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Infants in Special Care Nurseries
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Louise S. Owen, M.D., Jann P. Foster, Ph.D., Li Huang, Ph.D.,
Calum T. Roberts, Ph.D., Tracey L. Clark, Grad.Cert.Nur.(N.I.C.U.),
Wei‑Qi Fan, Ph.D., Alice Y.W. Fang, M.B., B.S., Isaac R. Marshall, M.P.H.,
Rosalynn J. Pszczola, M.B., Ch.B., Peter G. Davis, M.D.,
and Adam G. Buckmaster, Ph.D., for the HUNTER Trial Investigators*

A BS T R AC T
BACKGROUND

Nasal high-flow therapy is an alternative to nasal continuous positive airway pressure (CPAP) as a means of respiratory support for newborn infants. The efficacy
of high-flow therapy in nontertiary special care nurseries is unknown.
METHODS

We performed a multicenter, randomized, noninferiority trial involving newborn
infants (<24 hours of age; gestational age, ≥31 weeks) in special care nurseries in
Australia. Newborn infants with respiratory distress and a birth weight of at least
1200 g were assigned to treatment with either high-flow therapy or CPAP. The
primary outcome was treatment failure within 72 hours after randomization. Infants in whom high-flow therapy failed could receive CPAP. Noninferiority was
determined by calculating the absolute difference in the risk of the primary outcome, with a noninferiority margin of 10 percentage points.

The authors’ affiliations are listed in the
Appendix. Address reprint requests to
Dr. Manley at the Newborn Research
Centre, Royal Women’s Hospital, Level 7,
20 Flemington Rd., Parkville, VIC 3052,
Australia, or at brett.manley@thewomens
.org.au.
*A complete list of the HUNTER trial inves‑
tigators is provided in the Supplemen‑
tary Appendix, available at NEJM.org.
N Engl J Med 2019;380:2031-40.
DOI: 10.1056/NEJMoa1812077
Copyright © 2019 Massachusetts Medical Society.

RESULTS

A total of 754 infants (mean gestational age, 36.9 weeks, and mean birth weight,
2909 g) were included in the primary intention-to-treat analysis. Treatment failure
occurred in 78 of 381 infants (20.5%) in the high-flow group and in 38 of 373
infants (10.2%) in the CPAP group (risk difference, 10.3 percentage points; 95%
confidence interval [CI], 5.2 to 15.4). In a secondary per-protocol analysis, treatment failure occurred in 49 of 339 infants (14.5%) in the high-flow group and in
27 of 338 infants (8.0%) in the CPAP group (risk difference, 6.5 percentage points;
95% CI, 1.7 to 11.2). The incidences of mechanical ventilation, transfer to a tertiary neonatal intensive care unit, and adverse events did not differ significantly
between the groups.
CONCLUSIONS

Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in
a significantly higher incidence of treatment failure than CPAP when used in nontertiary special care nurseries as early respiratory support for newborn infants
with respiratory distress. (Funded by the Australian National Health and Medical
Research Council and Monash University; HUNTER Australian and New Zealand
Clinical Trials Registry number, ACTRN12614001203640.)
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linicians aim to avoid the use of
mechanical ventilation through an endotracheal tube in newborn infants with
respiratory distress by providing noninvasive respiratory support. In Australia, infants for whom
ongoing mechanical ventilation is indicated are
typically transferred to a tertiary-level neonatal
intensive care unit (NICU). Owing to potentially
large distances between regional or rural nontertiary special care nurseries and metropolitan
NICUs, a transfer may result in family disruptions, with associated psychosocial and financial costs.1,2
The use of nasal continuous positive airway
pressure (CPAP) in large Australian special care
nurseries is beneficial and cost-effective, and it
is associated with a lower incidence of treatment
failure or transfer to a NICU than supplemental
oxygen alone.3 Infants with respiratory distress
now routinely receive CPAP in large special care
nurseries in Australia. However, CPAP may be
associated with an increased incidence of pneumothorax,4 and experienced medical and nursing specialists are required in order to provide
CPAP safely and effectively; this precludes its use
in smaller special care nurseries in Australia5
and around the world. Nasal high-flow therapy
is an increasingly popular alternative to CPAP for
neonatal respiratory support.6-8 High-flow therapy
delivers heated, humidified gas at flows of
greater than 1 liter per minute through small
binasal prongs. It has a simple interface that is
easier to use and appears to be more comfortable than CPAP, and it is preferred by parents
and nurses.9,10
We previously found that when used in tertiarylevel NICUs as primary respiratory support for
preterm infants born at a gestational age of 28
weeks 0 days to 36 weeks 6 days, high-flow
therapy resulted in a significantly higher incidence of treatment failure than did CPAP.11 However, special care nurseries have far more mature
infants with fewer coexisting conditions than do
NICUs; they also differ from NICUs with respect
to medical and nursing experience and the ratio
of providers to patients. For these reasons, highflow therapy may be well suited to special care
nurseries. Since most late-preterm and term infants with respiratory distress receive treatment
in special care nurseries, data to guide respiratory support in this setting are relevant to many
thousands of infants in developed countries
each year.12 We performed the multicenter, ran2032
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domized, noninferiority High-Flow Use in NonTertiary Centres for Early Respiratory Distress
(HUNTER) trial in Australian special care nurseries to test the hypothesis that high-flow therapy is noninferior to CPAP as primary respiratory support for newborn infants with early
respiratory distress.

Me thods
Trial Design and Oversight

Eligible nontertiary centers were similar to level 2
special care nurseries as defined by the Committee on Fetus and Newborn of the American
Academy of Pediatrics.13 The driving time from
the centers to the closest tertiary NICU was up
to 90 minutes. The centers routinely cared for
infants born at or after 32 weeks of gestation,
and occasionally they cared for infants born at
31 weeks of gestation. At least 2000 births per
year occurred in each center, and all centers had
extensive experience treating infants with CPAP.
Multisite ethical approval was obtained from
the Royal Children’s Hospital, Melbourne, Australia, and site-specific approval was obtained
from each center. The authors vouch for the accuracy and completeness of the data and for the
fidelity of the trial to the protocol (published
previously14 and available with the full text of
this article at NEJM.org). The trial had no commercial support, and the manufacturers of the
respiratory devices had no input in the trial design, data accrual, data analysis, or manuscript
preparation and no access to the trial data.
Patients

Infants were eligible for inclusion if they were
born at a gestational age of 31 weeks 0 days or
later, had a birth weight of at least 1200 g, were
less than 24 hours of age, and if the treating
clinician determined that noninvasive respiratory support was indicated, the infant had received
supplemental oxygen for more than 1 hour, or
both. Since CPAP treatment was the standard
of care for respiratory distress, up to 2 hours of
CPAP treatment was permitted while consent
was sought. Infants were ineligible if, before
randomization, they had received CPAP for more
than 2 hours, had undergone endotracheal intubation, had a known major congenital abnormality, or if the treating clinician had decided
that endotracheal intubation or transfer to a
NICU was indicated.
nejm.org
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Consent and Randomization

The parent or parents of all participating infants
provided written informed consent before randomization. A computer-generated randomization sequence with variable block sizes was
used. Infants were stratified according to gestational age (<34 weeks vs. ≥34 weeks) and trial
center. Enrolled infants who were part of multiple births underwent randomization individually. Sequentially numbered, sealed, opaque envelopes containing the treatment assignment
were opened once eligibility criteria were met
and consent was obtained.
Trial Intervention

Eligible infants were randomly assigned to treatment with either high-flow therapy or CPAP
generated with the use of an underwater “bubble” system. Other aspects of care were provided
according to local protocols, including blood gas
analysis, chest radiography, intravenous fluids,
and enteral feeding.
Infants assigned to the high-flow group received an initial gas flow of 6 liters per minute
from the Optiflow Junior device (Fisher and
Paykel Healthcare). The maximum permissible
gas flow was 8 liters per minute, consistent with
the maximum gas flow used in previous studies.11,15,16 Infants assigned to high-flow therapy
who met the criteria for treatment failure could
receive CPAP as rescue therapy, initiated at a
pressure of 8 cm of water.
In infants who were assigned to CPAP, the
starting pressure was 6 cm of water delivered
through short binasal prongs or a nasal mask.
The maximum permissible CPAP pressure was
8 cm of water. The trial protocol recommended
that infants from either group who met the criteria for treatment failure while receiving CPAP
be discussed with members of the local neonatal
retrieval service and receive endotracheal intubation as appropriate. The decision to transfer the
infant to a NICU remained with the treating
clinician, irrespective of whether the criteria for
treatment failure were met. High-flow therapy
was not permitted for infants in the CPAP group.
Guidance on weaning and discontinuation of
respiratory support was included in the trial
protocol.14

receiving maximal support (gas flow of 8 liters
per minute [in the high-flow group] or pressure
of 8 cm of water [in the CPAP group]) were considered to have treatment failure if they met one
or more of the following criteria: a fraction of
inspired oxygen of 0.4 or higher for more than
1 hour to maintain target oxygen saturation
levels of 91 to 95%; a pH of less than 7.2 plus a
partial pressure of carbon dioxide greater than
60 mm Hg in two samples of arterial or capillary
blood obtained at least 1 hour after commencement of the assigned treatment and obtained
1 hour apart; or two or more episodes of apnea
for which positive-pressure ventilation was indicated within a 24-hour period or six or more
episodes for which any intervention was indicated within a 6-hour period. Infants who had
an urgent need for endotracheal intubation and
mechanical ventilation or required transfer to a
NICU (as determined by the treating clinician)
were also considered to have treatment failure.
Infants in whom respiratory management was
escalated at the discretion of the clinician and
who had not clearly met the criteria for treatment failure were classified as having another
reason for treatment failure.
Prespecified secondary outcomes included
the reason or reasons for treatment failure; endotracheal intubation; transfer to a NICU; the
duration of respiratory support, supplemental
oxygen, and hospitalization; and the cost of
care. The complete list of prespecified secondary
outcomes is provided in the trial protocol14 and
in Section 2 in the Supplementary Appendix,
available at NEJM.org. The methods for the costof-care analysis are also provided Section 3 in
the Supplementary Appendix.
Statistical Analysis

On the basis of recent admission data from participating centers, we estimated that treatment
failure within 72 hours after randomization
would occur in 17% of the infants assigned to
receive CPAP. We prespecified a noninferiority
margin for high-flow treatment of 10 percentage
points above the failure rate for CPAP treatment.
Data from previous trials comparing high-flow
therapy with CPAP in the nontertiary setting on
which to base our sample-size calculation were
lacking. We chose this margin of noninferiority
Trial Outcomes
on clinical grounds, taking into consideration
The primary outcome was treatment failure that infants in whom high-flow treatment failed
within 72 hours after randomization. Infants could receive CPAP treatment, which we hypothn engl j med 380;21
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esized might obviate the need for endotracheal
intubation. The pediatricians, neonatologists,
and parent representatives consulted during the
trial-design phase agreed that a treatment failure rate that was 10 percentage points higher
with high-flow therapy than with CPAP would
be the maximum acceptable rate. High-flow
therapy would thus be considered noninferior to
CPAP if the upper limit of the two-sided 95%
confidence interval for the risk difference was
less than 10 percentage points. For the trial to
have 90% power, a sample of 750 infants was
required (one-sided alpha level of 0.025).
In accordance with the prespecified statistical analysis plan (available with the protocol at
NEJM.org), we performed both a primary intention-to-treat analysis and a secondary per-protocol analysis, as recommended for noninferiority
trials.17 The intention-to-treat analysis included
all eligible infants for whom consent had been
provided. Exclusion criteria for the per-protocol
analysis were determined prospectively (see Section 4 in the Supplementary Appendix). Both
analyses were performed without adjustment
and with adjustment for gestational age, trial
center, birth weight, exposure to antenatal glucocorticoids (<7 days before birth), and sex; analyses with adjustment were designated as secondary analyses.
Secondary outcomes were analyzed on an
intention-to-treat basis. A prespecified subgroup
analysis according to gestational age (<34 weeks
or ≥34 weeks) was performed for the primary
outcome and selected secondary outcomes; heterogeneity was assessed by including an interaction
term in the models. Since we did not prespecify
a plan to adjust for multiple secondary outcomes, we do not report P values for these
outcomes.
For the primary outcome and dichotomous
secondary outcomes, we calculated a risk difference (with a two-sided 95% confidence interval)
in percentage points between the treatment
groups. Since the widths of the confidence intervals were not adjusted for multiple comparisons,
the intervals should not be used to infer definitive treatment effects for secondary outcomes.
We used chi-square tests to compare dichotomous outcomes, the appropriate parametric test
(Student’s t-test) or nonparametric test (difference in medians estimated by quantile regression) to compare continuous outcomes, and
2034
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Figure 1 (facing page). Numbers of Infants Who Were
Screened, Assigned to a Trial Group, and Included
in the Primary and Secondary Analyses.
Infants who were born at a gestational age of 31 weeks
0 days or later, had a birth weight of at least 1200 g,
and had a clinical diagnosis of respiratory distress were
screened for eligibility. (Additional information regard‑
ing infants who did not meet the treatment-failure cri‑
teria before respiratory support was escalated is pro‑
vided in Section 4 in the Supplementary Appendix).
CPAP denotes continuous positive airway pressure.

generalized linear models for analyses with adjustment. All analyses were performed with the
use of SAS software, version 9.4 (SAS Institute),
or Stata software, version 14.0 (StataCorp).
An independent data and safety monitoring
committee undertook a planned review of the
primary outcome at the midpoint of the trial.
Safety analyses for predefined serious adverse
events, blinded to the intervention, were undertaken after recruitment of 150 infants (20%),
375 infants (50%), and 562 infants (75%).

R e sult s
Recruitment

Infants were recruited from April 13, 2015,
through November 28, 2017, at nine Australian
nontertiary centers. The data and safety monitoring committee performed interim efficacy
and safety reviews as planned and recommended that the trial continue unaltered.
Trial Patients

In total, 768 infants were randomly assigned to
a treatment group (385 to the high-flow group
and 383 to the CPAP group). Fourteen infants
were excluded because they did not meet the eligibility criteria or their parents did not provide
consent or withdrew consent. A total of 754
infants (mean gestational age, 36.9 weeks, and
mean birth weight, 2909 g) were included in the
primary intention-to-treat analysis (381 in the
high-flow group and 373 in the CPAP group) and
were followed until hospital discharge or death
(Fig. 1). The demographic and clinical characteristics of the mothers and infants included in the
intention-to-treat analysis were similar in the
two groups (Table 1). After exclusion of 77 infants (42 in the high-flow group and 35 in the
CPAP group), 677 infants were included in the
nejm.org

May 23, 2019

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on June 4, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

Nasal High-Flow Ther apy for Newborns

1415 Infants were assessed for eligibility

105 Were excluded (74 had one reason, 31 had
two reasons)
16 Had >2 hr of CPAP after admission
60 Underwent previous endotracheal
intubation or had to undergo
immediate endotracheal intubation
11 Had known major congenital abnormality
49 Were transferred to another hospital

1310 Were eligible

542 Did not undergo randomization
295 Had parents who were not approached
for consent (290 were not approached for
one reason, 5 were not approached for
two reasons)
30 Had parents who were not approached
for consent because staff were not
available
38 Had parents who were unavailable to
provide consent
25 Had parents with language barrier and
interpreter was not available
84 Had parents who were not approached
by clinician
68 Had other reason
55 Had unknown reason
6 Had parents who provided consent but
did not undergo randomization
241 Had parents who declined to participate

768 Underwent randomization

385 Were assigned to high-flow group

383 Were assigned to CPAP group

10 Were excluded
5 Underwent randomization
in error
4 Did not have consent
1 Had consent withdrawn

4 Were excluded
1 Underwent randomization
in error
2 Did not have consent
1 Had consent withdrawn
381 Were included in the 72-hr follow-up
after randomization and included
in the primary intention-to-treat analysis

373 Were included in the 72-hr follow-up
after randomization and included
in the primary intention-to-treat analysis

42 Were excluded from the perprotocol analysis
18 Did not receive assigned
treatment
24 Were not treated
according to treatmentfailure criteria protocol

35 Were excluded from the perprotocol analysis
24 Did not receive assigned
treatment
11 Were not treated
according to treatmentfailure criteria protocol

339 Were included in the per-protocol
analysis

n engl j med 380;21
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Table 1. Baseline Characteristics of the Mothers and Infants.*
High-Flow Group
(N = 381)

CPAP Group
(N = 373)

29.8±5.6

30.1±5.7

Multigravida — no. (%)

209 (54.9)

169 (45.3)

Use of antenatal glucocorticoids <7 days before birth — no. (%)

107 (28.1)

91 (24.4)

Labor — no. (%)

263 (69.0)

265 (71.0)

Cesarean section — no. (%)

204 (53.5)

177 (47.5)

Ruptured membranes ≥24 hr before delivery — no. (%)†

36 (9.4)

33 (8.8)

Chorioamnionitis — no. (%)

14 (3.7)

9 (2.4)

Meconium-stained amniotic fluid — no. (%)

77 (20.2)

74 (19.8)

36.9±2.8

36.9±3.0

Characteristic
Mothers
Age — yr

Infants
Gestational age
No. of weeks

72 (18.9)

68 (18.2)

Birth weight — g

<34 wk — no. (%)

2936±786

2885±790

Male sex — no. (%)

246 (64.6)

237 (63.5)

Multiple birth — no. (%)

26 (6.8)

37 (9.9)

8.0 (7.0–9.0)

8.0 (7.0–9.0)

60 (15.7)

70 (18.8)

55.0 (30–90)

46.0 (28–70)

216 (56.7)

209 (56.0)

pH¶

7.20±0.09

7.20±0.09

Partial pressure of carbon dioxide — mm Hg‖

64.5±14.1

63.8±14.4

Fraction of inspired oxygen before randomization**

26.9±9.6

27.5±11.6

Median Apgar score at 5 min (IQR)‡
Treatment with CPAP before randomization§
No. of infants (%)
Median duration (IQR) — min
Blood gas analysis before randomization — no. (%)

*	Plus–minus values are means ±SD. There were no significant differences between the two groups, except in the mul‑
tigravida category (P<0.05). CPAP denotes continuous positive airway pressure, and IQR interquartile range.
†	Data on ruptured membranes were missing for one infant in the CPAP group.
‡	The 5-minute Apgar score was not known for one infant in the high-flow group and three infants in the CPAP group.
§	It was not known whether CPAP was used before randomization in one infant in the CPAP group.
¶	Data on pH were missing for one infant in the CPAP group.
‖	Data on the partial pressure of carbon dioxide were missing for one infant in the high-flow group.
**	Data on the fraction of inspired oxygen were missing for two infants in the high-flow group and two infants in the
CPAP group.

per-protocol analysis (Fig. 1). The demographic
characteristics of the per-protocol population
are shown in Table S1 in the Supplementary Appendix.
Primary Outcome

In the intention-to-treat analysis, treatment failure within 72 hours after randomization occurred
in 78 of the 381 infants (20.5%) randomly assigned to high-flow therapy and in 38 of the 373
infants (10.2%) randomly assigned to CPAP (risk
difference, 10.3 percentage points; 95% confidence interval [CI], 5.2 to 15.4). High-flow ther
2036
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apy was therefore not shown to be noninferior
and, since zero was excluded from the 95% confidence interval, CPAP was statistically superior
(Table 2); a Kaplan–Meier survival curve of these
data is shown in Figure S1 in the Supplementary
Appendix. Results of adjusted analyses yielded
similar results (Table 2). In the per-protocol
analysis, treatment failure within 72 hours after
randomization occurred in 49 of the 339 infants
(14.5%) in the high-flow group and in 27 of the
338 infants (8.0%) in the CPAP group (risk difference, 6.5 percentage points; 95% CI, 1.7 to
11.2), also indicating that high-flow therapy was
nejm.org
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Table 2. Primary Outcome in the Intention-to-Treat and Per-Protocol Analyses.*
Outcome

All
Patients

High-Flow Group
(N = 381)

CPAP Group
(N = 373)

Risk Difference (95% CI)†
Univariate
Analysis

no.

Adjusted
Analysis‡

no./total no. (%)

Intention-to-treat analysis
Treatment failure within 72 hr
after randomization

754

78/381 (20.5)

38/373 (10.2)

Gestational age <34 wk

140

20/72 (27.8)

Gestational age ≥34 wk

614

58/309 (18.8)

26/305 (8.5)

677

49/339 (14.5)

27/338 (8.0)

6.5 (1.7 to 11.2)

5.5 (0.5 to 10.4)

12/68 (17.6)

10.3 (5.2 to 15.4)§

9.2 (3.9 to 14.5)

10.1 (−3.6 to 23.9)

8.7 (−5.8 to 23.1)

10.3 (4.9 to 15.6)§

8.3 (2.7 to 14.0)

Per-protocol analysis
Treatment failure within 72 hr
after randomization
Gestational age <34 wk

129

14/65 (21.5)

Gestational age ≥34 wk

548

35/274 (12.8)

10/64 (15.6)
17/274 (6.2)

5.9 (−7.5 to 19.3)

6.0 (−8.0 to 19.9)

6.6 (1.7 to 11.5)

5.5 (0.2 to 10.7)

*	P = 0.99 for the interaction in the intention-to-treat analysis and P = 0.93 for the interaction in the per-protocol analysis (both unadjusted).
On the basis of a noninferiority margin of 10 percentage points, high-flow therapy was not noninferior to CPAP in all analyses. CI denotes
confidence interval.
†	Apart from the primary analysis (univariate intention-to-treat analysis for all infants), other differences in risk are secondary outcomes that
were not adjusted for multiple outcomes, and inferences drawn from these intervals may not be reproducible.
‡	The analysis was adjusted for stratification variables (gestational-age group and trial center) and prespecified confounders (birth weight, ex‑
posure to antenatal glucocorticoids, and sex). Data from hospitals with a low incidence of treatment failure were aggregated before control‑
ling for trial center in all per-protocol analyses and for the intention-to-treat analysis involving infants younger than 34 weeks of gestational
age; different levels of aggregation were used in each analysis (see Section 6 and Table S3 in the Supplementary Appendix).
§	P<0.001.

not noninferior to CPAP. A Kaplan–Meier survival curve of the data for the per-protocol population is shown in Figure S2 in the Supplementary Appendix.
A prespecified analysis according to gestational
age showed similar findings in the two subgroups
(Table 2) (P = 0.99 for the interactions in both
the unadjusted and adjusted models). Post hoc
sensitivity analyses excluding infants who received
CPAP before randomization yielded similar results
(Table S4 in the Supplementary Appendix). A
small percentage of infants who underwent randomization in the intention-to-treat population
(3.7%) were twin pairs who underwent randomization individually; results of a post hoc sensitivity analysis excluding these infants are shown
in Table S5 in the Supplementary Appendix.
Secondary Outcomes and Adverse Events

All secondary outcomes and adverse events are
presented for the intention-to-treat population.
The secondary outcome for the per-protocol
population (transfer to a tertiary-level NICU) is
included in Table S2 in the Supplementary Appendix.
n engl j med 380;21

Secondary outcomes and adverse events are
listed in Table 3. The reasons for treatment failure are listed in Table S6 in the Supplementary
Appendix. The most common reason for treatment failure in the two trial groups was a fraction of inspired oxygen of at least 0.40 for more
than 1 hour. Treatment failure due to apnea occurred more frequently in the high-flow group
than in the CPAP group. The most common
other reason for treatment failure in the highflow group was escalation of therapy in infants
in whom the criteria for treatment failure had
not been met (in 17 of 23 infants). In the CPAP
group, the most common other reason for treatment failure was pneumothorax (in 8 of 11 infants).
Of the 78 infants in the high-flow group in
whom treatment failure occurred, 62 infants
received backup CPAP during the primary outcome period, and 32 were not intubated or
transferred to a NICU within 72 hours after
randomization. The incidences of mechanical
ventilation and transfer to a NICU did not differ
significantly between the groups. The median
duration of respiratory support and the median
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Table 3. Secondary Outcomes and Adverse Events.*
High-Flow Group
(N = 381)

Outcome

CPAP Group
(N = 373)

Difference (95% CI)†
percentage points

Mechanical ventilation through an endotracheal tube — no. (%)
<72 hr after randomization

21 (5.5)

22 (5.9)

−0.4 (−3.7 to 2.9)

At any time after randomization

25 (6.6)

22 (5.9)

0.7 (−2.8 to 4.1)

<72 hr after randomization

39 (10.2)

32 (8.6)

1.7 (−2.5 to 5.8)

At any time after randomization

Transfer to tertiary NICU — no. (%)‡
49 (12.9)

41 (11.0)

1.9 (−2.8 to 6.5)

Surfactant treatment <72 hr after randomization — no. (%)

21 (5.5)

22 (5.9)

−0.4 (−3.7 to 2.9)

Median no. of hr of respiratory support after randomization (IQR)

20 (10 to 48)

15 (7 to 35)

5.0 (1.5 to 8.5)

5 (0 to 18)

1 (0 to 14)

4.0 (2.1 to 5.9)

Median no. of hr of supplemental oxygen (IQR)
Final respiratory diagnosis — no. (%)§
Transient tachypnea of the newborn

169 (44.4)

160 (42.9)

Respiratory distress syndrome

161 (42.3)

162 (43.4)

NC

4 (1.1)

11 (2.9)

NC

47 (12.3)

40 (10.7)

NC

163 (42.8)

155 (41.6)

Pneumothorax
Other
Full breast-feeding at hospital discharge — no. (%)

NC

1.2 (−5.8 to 8.3)

Median no. of days of intravenous fluids after randomization (IQR)

3 (2 to 5)

3 (2 to 5)

Median age at start of full-suck feeding (IQR)¶

4 (2 to 13)

4 (2 to 14)

0 (−1.2 to 1.2)

−2.4±9.2

−1.9±9.1

−0.5 (−1.8 to 0.8)

7 (3 to 18)

7 (4 to 17)

0 (−2.2 to 2.2)

Weight gain from birth to final hospital discharge — g/kg/day

0.0 (−0.3 to 0.3)

Median no. of days in hospital (IQR)
Total no. of days in any hospital
Tertiary NICU‖

6.9 (5.0 to 11.5)

Death before hospital discharge — no. (%)**,††

5.8 (3.3 to 11.8)

1.1 (−2.1 to 4.3)

2 (0.5)

0

0.5 (−0.2 to 1.3)

2 (0.5)

0

0.5 (−0.2 to 1.3)

0

0

NC

Supplemental oxygen or respiratory support
At 28 days of life; born ≥32 wk gestational age‡‡
At 36 wk postmenstrual age; born <32 wk gestational age§§
Pneumothorax diagnosed after randomization
Any

23 (6.0)

28 (7.5)

−1.5 (−5.1 to 2.1)

Drained with needle thoracocentesis or intercostal catheter**

9 (2.4)

18 (4.8)

−2.5 (−5.1 to 0.2)

Nasal trauma after randomization

2 (0.5)

6 (1.6)

−1.1 (−2.6 to 0.4)

*	Plus–minus values are means ±SD. NC denotes not calculated, and NICU neonatal intensive care unit.
†	Differences were calculated as the difference in percentages for dichotomous data or as the difference in medians or means for continu‑
ous data. These differences have not been adjusted for multiple comparisons, and inferences drawn from these intervals may not be re‑
producible.
‡	This category includes decisions made by a clinician after treatment failure to transfer an infant to a NICU.
§	This outcome was not included in the original statistical analysis plan, but it was added as a post hoc comparison. The final respiratory di‑
agnosis was based on the discharge summary provided by the clinician who was caring for the infant. Cases in which there were major in‑
consistencies between the clinical course and the recorded diagnosis were reviewed by the investigators and clinicians who were unaware
of the treatment group, and a diagnosis was reached by consensus.
¶	The age at the start of full-suck feeding was missing for 10 infants in the high-flow group and 4 infants in the CPAP group.
‖	Data shown are for 49 infants in the high-flow therapy group and 41 infants in the CPAP group who were admitted to a NICU at any time
before final discharge.
**	These events were specified as serious adverse events in the trial.
††	Both deaths occurred after 1 month of age in association with genetic conditions; these deaths were determined by the investigators to be
unrelated to the trial intervention.
‡‡	Data shown are for 731 infants (368 in the high-flow group and 363 in the CPAP group); 7 infants were never assessed (4 in the high-flow
group and 3 in the CPAP group).
§§	Data shown are for 16 infants (9 in the high-flow group and 7 in the CPAP group); all infants were assessed.
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number of hours after birth at which supplemental oxygen was discontinued were higher in
the high-flow group than in the CPAP group.
The incidence of adverse events did not differ
significantly between the groups (Table 3).
There were no significant differences in the
calculated mean costs of nontertiary special care
nursery hospital stays, tertiary NICU stays, or
interhospital transfers between the two groups.
More information is provided in Section 3 in the
Supplementary Appendix.

Discussion
In this multicenter, randomized trial comparing
two types of primary respiratory support for
newborn infants in nine Australian nontertiary
special care nurseries, high-flow treatment was
not shown to be noninferior to CPAP for preventing treatment failure within the first 72
hours after randomization in the primary intention-to-treat analysis or in the secondary perprotocol analysis. Both analyses suggested that
CPAP was superior to high-flow therapy.
High-flow therapy was successful in approximately 80% of the infants and, with CPAP available as backup treatment when primary highflow therapy failed, there was no increase in the
need for mechanical ventilation or NICU transfer or in adverse events. It is plausible that the
use of backup CPAP was responsible for avoiding
intubation or NICU transfer in up to 32 of 78
infants (41%) in the high-flow group with treatment failure. Our previous noninferiority studies
of high-flow therapy in preterm infants also
showed that the use of backup CPAP prevented
intubation in almost half the infants in whom
high-flow treatment failure occurred.11,15 Infants
in the high-flow group received respiratory support for a median of 5 hours longer and supplemental oxygen for a median of 4 hours longer
than the infants in the CPAP group, but the
clinical importance of these differences is uncertain. Interpretation of these results may vary
according to the circumstances of individual
treatment centers. Important considerations include the number of staff, staff expertise, and
the distances to treatment centers offering mechanical ventilation. Although high-flow therapy
was not noninferior, the facts that CPAP served
as effective backup therapy and that many infants
were successfully treated with high-flow therapy
n engl j med 380;21

mean that these results may not preclude a role
for high-flow therapy in treating some newborn
infants.
We included infants born at 31 weeks of gestational age or later, with a birth weight of at
least 1200 g; this population was representative
of the usual population cared for in Australian
nontertiary special care nurseries. The results of
this trial are consistent with those of previous
randomized trials comparing high-flow therapy
with CPAP as early respiratory support for preterm infants in NICUs who have not received
exogenous surfactant treatment.18,19
A previous noninferiority trial11 involving preterm infants born at 28 to 36 weeks of gestation
and cared for in tertiary-level NICUs was discontinued early when CPAP was shown at the interim
analysis to be superior to high-flow therapy at
preventing treatment failure. That trial also
showed that the use of high-flow therapy in
conjunction with rescue CPAP did not result in
important adverse outcomes. It is possible that
inconsistent generation of distending pressures
with high-flow therapy may account for the difference in the incidence of treatment failure.20-23
Other studies comparing high-flow therapy with
CPAP as primary respiratory support for preterm
infants have shown little difference between the
treatments,24,25 but this may be explained by the
use of exogenous surfactant before determination of the primary outcome. Administration of
exogenous surfactant is unlikely to be generalizable to special care nurseries, where it is challenging for clinicians to maintain the skills required for delivery of surfactant.
Blinding of the intervention in our trial was
not possible. To minimize bias, we used prespecified, objective criteria to determine the
primary outcome. The use of backup CPAP may
have influenced the incidences of secondary
outcomes in the high-flow group. We took a
pragmatic approach of including infants who
had received up to 2 hours of CPAP before randomization. Post hoc sensitivity analyses excluding these infants did not show a material difference in the results.
In conclusion, in this trial with a margin of
noninferiority of 10 percentage points, we found
that high-flow therapy was not noninferior to
CPAP. High-flow therapy resulted in a significantly higher incidence of treatment failure than
CPAP when used as early respiratory support for
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newborn infants with respiratory distress in nontertiary special care nurseries.
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